The DOI matches its Crossref record; the references it cites are not checked yet.
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
Open accessAbstract
Background Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis.Methods The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR) of 3·2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS28-ESR change from baseline to week 24, with a difference of more than 0·6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov, NCT02573012.Findings Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08 (-0·27 to 0·12) with continued prednisone (difference 0·61 [0·35-0·88]; p<0·0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0·83; 95% CI 0·71-0·97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency.Interpretation In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose.Funding F Hoffmann-La Roche.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After long-term use of glucocorticoids, more rapid tapering of glucocorticoids when on a supraphysiologic dosing, followed by a slower taper when on physiologic glucocorticoid dosing, appears to be a safe strategy (42, 52).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [52]
In the citing paper
“In the SEMIRA Study,10 continuation of low-dose prednisone (5 mg/day) in patients who achieved low disease activity with tocilizumab was safe and demonstrated a better disease control than tapering.”
From Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study (2024) · cites this paper as [10]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 38 · Cited by 128
Metadata
- Authors
- Burmester, G. R., Buttgereit, F., Bernasconi, C., Álvaro-Gracia, J. M., Castro, N., Dougados, M., Gabay, C., van Laar, J. M., Nebesky, J. M., Pethoe-Schramm, A., Salvarani, C., Donath, M. Y., John, M. R., Constantin, A., Gottenberg, J. E., Loiseau-Peres, S., Nguyen, M., Schaeverbeke, T., Alten, R. H.-E., Amberger, C., Biewer, W. A., Boche, K., Burmester, G. R., Engel, A., Feuchtenberger, M., Fleck, M., Gauler, G., Heilig, B., Höhle, M., Iking-Konert, C., Kästner, P., Kofler, D., Krueger, K., Kühne, C., Kurthen, R., Schulze-Koops, H., Schwenke, H., Sieburg, M., Specker, C., Tony, H.-P., Wassenberg, S., Wendler, J., Caporali, R., Epis, O., Matucci-Cerinic, M., Salvarani, C., Dubikov, A., Kamalova, R., Korolev, M., I. Mazurov, V., Puntus, E., Damjanov, N., Ilic, T., Lazarevic, M., Milenkovic, S., Petronijevic, M., Gabay, C., Bouajina, E., & Elleuch, M.
- Affiliations
- Humboldt-Universität zu Berlin (DE)
- F. Hoffmann-La Roche AG (CH)
- Université Paris Descartes (FR)
- University Hospital of Basel (CH)
- Corresponding author
- Burmester, Gerd R
- ORCID
- Burmester, Gerd R
- Buttgereit, Frank
- Bernasconi, Corrado
- Dougados, Maxime
- Donath, Marc Y
- Constantin, Arnaud
- Gottenberg, Jacques Eric
- Nguyen, Minh
- Schaeverbeke, Thierry
- Feuchtenberger, Martin
- Fleck, Martin
- Gauler, Georg
- Kofler, David
- Krueger, Klaus
- Schwenke, Holger
- Specker, Christof
- Wassenberg, Siegfried
- Epis, Oscar
- Korolev, Maxim
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 396
- Issue
- 10246
- Pages
- 267-276
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3044002186
- Cited by
- 128
- References
- 38
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 26 · 2023: 28 · 2022: 23 · 2021: 20 · 2020: 10
- FWCI
- 15.24
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- HAL (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- rheumatoid arthritis, glucocorticoid tapering, prednisone, low-dose glucocorticoids, tocilizumab, disease activity, remission, DAS28-ESR, csDMARDs, steroid-sparing therapy, glucocorticoid adverse effects, treatment discontinuation, disease flares
- MeSH terms
- Administration, Oral, Adult, Aged, Arthritis, Rheumatoid, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, France, Germany, Glucocorticoids, Humans, Injections, Subcutaneous, Italy, Male, Middle Aged, Prednisone, Remission Induction, Russia, Tunisia, Outcome Assessment, Health Care, Serbia, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30636-x
- The paper
- Burmester, G. R., Buttgereit, F., Bernasconi, C., Álvaro-Gracia, J. M., Castro, N., Dougados, M., Gabay, C., van Laar, J. M., Nebesky, J. M., Pethoe-Schramm, A., Salvarani, C., Donath, M. Y., John, M. R., Constantin, A., Gottenberg, J. E., Loiseau-Peres, S., Nguyen, M., Schaeverbeke, T., Alten, R. H.-E., . . . Elleuch, M. (2020). Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30636-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.